CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Liraglutide 0.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02647944
NCT02647944Phase 2Completed
CompareCT.gov

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Mayo Clinic·interventional·Posted Jan 6, 2016·Updated Oct 27, 2017

In Brief

A Phase 2 clinical trial evaluating Liraglutide and Placebo for Obesity. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 6, 2016
Enrollment StartDec 18, 2015
Primary CompletionDec 30, 2016
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.5 years ago

Interventions

Liraglutidedrug

Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.

Placebodrug